Research Use of Ecological Momentary Assessment for Adverse Event Monitoring Following Amyloid-β Results Disclosure
| Autor: | Lisa Tamres, Richard Schulz, Meghan Mattos, Susan M. Sereika, Neelesh K. Nadkarni, Scott R. Beach, Jennifer H. Lingler, William E. Klunk, Hyejin Kim, J. Scott Roberts, Lisa S. Parker, Melissa Knox |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Ethics Review
0301 basic medicine Amyloid Ecological Momentary Assessment Plaque Amyloid Disease Truth Disclosure Ethics Research Suicidal Ideation law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial Alzheimer Disease cognitive dysfunction law Positron Emission Tomography Computed Tomography medicine Humans Adverse effect Suicidal ideation Depression (differential diagnoses) Amyloid beta-Peptides Ecology business.industry General Neuroscience General Medicine research subjects Prognosis ethics 3. Good health Affect Psychiatry and Mental health Clinical Psychology 030104 developmental biology Mood Biomarker (medicine) Anxiety Geriatrics and Gerontology medicine.symptom business 030217 neurology & neurosurgery |
| Zdroj: | Journal of Alzheimer's Disease |
| ISSN: | 1875-8908 1387-2877 |
| Popis: | As calls for transparency in human subjects research grow, investigators conducting Alzheimer’s disease (AD) biomarker research are increasingly required to consider their ethical obligations regarding the return of AD biomarker test results to research participants. When disclosing these test results to potentially vulnerable participants, investigators may face unique challenges to identify adverse events, particularly psychological events. The purpose of this paper is to describe our research team’s experience with developing and implementing a process for enhanced adverse event monitoring following the return of amyloid-β (Aβ) imaging results to research participants with mild cognitive impairment (MCI). Ethical and logistical considerations are presented along with preliminary findings from an ongoing randomized controlled trial of Aβ imaging results disclosure in MCI. Following receipt of amyloid imaging results, participants underwent 14 days of adverse event monitoring using ecological momentary assessment (EMA), a strategy to capture health, behaviors, and mood as they occur in participants’ natural settings in real time. EMA telephone calls were placed at random during waking hours to screen for mood changes. Investigators were alerted for positive depression, anxiety, suicidal ideation screenings, or for two days of failed call attempts. Preliminary feasibility of twenty-four participants with MCI who participated in EMA mood assessments was successfully completed 83% (SD = 0.4) of the time over 14 days with no alerts for anxiety or depression screening items. EMA, when used with standard adverse event monitoring, is a promising and novel approach to maximize early detection of negative psychological reactions following AD biomarker results disclosed in research settings. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|